I need help to solve it please as soon as possible.

AutoSave On 2 HW1402_SPRING_2021 Version 1 (2) (1) (1) (1) - Saved - Search Rachid Sarhane RS File Home Insert Page Layout Formulas Data Review View Help Share Comments 11 Calibri 11 = = - AP > ab Wrap Text General 47 O FO Insert 3X Delete Format Paste .00 BIU A += = 3 Merge & Center $ % 40 .00 Conditional Format as Cell Formatting Table Styles Styles Sort & Find & Filter Select Analyze Data Clipboard Font Alignment Number Cells Editing Analysis 1112 X C. J K L P R S T U 25 26 B LACLIPOTIUT CICCICU VICTCK TUK TITS T-SUTUS TITUXITUMU TIIVUTT-SUCC. E mun Eng vua. H N 24 "Global sales of Invanz, for the treatment of certain infections, were $602 million in 2017, an increase of 7% compared with 2016, driven primarily by higher sales in the United States, reflecting higher pricing that was partially offset by lower demand, as well as higher demand in Brazil. Worldwide sales of Invanz were $561 million in 2016, a decline of 1% compared with 2015.... Sales performance in 27 2016 reflects higher pricing in the United States, largely offset by a decline in Venezuela. The patent that provided U.S. market exclusivity for invanz expired in November 2017 and the Company 28 anticipates a significant decline in U.S. Invanz sales in future periods. 29 32 33 34 35 30 After patent protection ends for Invanz, generic drug producers will likely introduce lower cost, generic versions of the product. The speed and size of generic entries will depend on numerous factors, 31 including the attractiveness of market entry by generic manufacturers, the investment required and the technological difficulty of manufacturing the product. While antibiotics such as Invanz are extremely capital-intensive and difficult to manufacture (due to processing complexity and the difficulty in maintaining acceptable conformance quality), generics are making inroads in Merck's other off-patent antibiotics. Patent protection for Primaxin ended in 2008 and a generic version entered the global market in 2010. 36 Merck lost patent protection for Invanz in the US in November 2017. On June 28, 2018, Aurobindo announced that the FDA had approved their generic versions have been approved for use in the US. 37 Aurobindo began selling generic Invanz in the US at the end of July 2018. 38 39 40 41 Invanz is an antibiotic of "last resort" meaning that it is typically only administered after other antibiotics have failed. The increasing incidence of infections that are resistant to more common antibiotics is expected to help offset inroads from generics. Clinical researchers estimate annual growth in demand for antibiotics such as Invanz in the low single digits annually for the foreseeable future due to increasing antibiotic resistance. 42 43 44 48 50 Demand for Invanz produced by Merck will be dependent in large part on Merck's ability to compete on cost as well as quality. Performance quality (i.e., the ability to successfully treat specific 45 infections) is an order winner. Conformance quality (i.e., meeting manufacturing specifications) is an order qualifier. Conformance quality issues are a serious concern; if poor quality product reaches 46 the market, patient safety could be at risk and the firm may need to conduct a product recall. Product recalls are typically damaging to the firm's stock price in the short term and potentially to the 47 firm's brand in the long term. Competing on cost will become increasingly important as new antibiotics enter the market and due to expected competition from firms producing generic versions of Invanz. Generic drug manufacturers may have higher quality risk when introducing new drugs, in part because they lack experience with the process. Merck has an advantage over Aurobindo in this 49 respect, at least initially, because they have lengthy production experience with the process. 51 52 Global sales of Invanz and Primaxin are provided below through the end of September 2018. A single dose of Invanz (1 bottle) retails, on average, at $1,315.56 per bottle; a single dose of Primaxin (1 53 bottle) is priced, on average, at $860.70 per bottle. You can assume that this pricing will remain constant over the period of the strategic plan and that generic competition is present worldwide as of 54 July 2018. You may assume that Aurobindo has a slight cost (price) advantage over Merck for Invanz, and that Aurobindo has adequate capacity to supply global demand for Invanz. A new strategic 55 plan is required for 2019-2023, including annual forecasts of sales of both products. 56 1. Scenario Details 2. Long Term Forecast | 3. Weekly Demand Forecast Sheet1 4. Process F... + Calculate + 70% H Type here to search O & . w AEC ENG 5:48 PM 4/13/2021 714 Content + AutoSave Off HD HW1&2_SPRING_2021 Version 1 (6) - Excel Search Rachid Sarhane RS File Home Insert Page Layout Formulas Data Review View Help Share Comments X Calibri 14 ' ' = > v a Wrap Text General AY o FO Insert 9X Delete Format Paste BIU a-A- ===== = .00 Merge & Center $ % Conditional Format as Cell Formatting Table Styles Styles Sort & Find & Filter Select Analyze Data Analysis Clipboard Font Alignment Number Cells Editing A31 X How many bottles, on average, are lost each year due to conformance quality failures (ALL LINES)? B c E F K L M N R R P s T U Y 5 FIRST AND LAST NAME 7 12 Step 12 Step 13 Step 14 Step 15 Step 16 13 14 16 Use the table below to show/calculate all steps of the process described (including activities and buffers). Provide the average inventory, rate, and time for each activity and buffer. 10 Use Little's Law and the data provided to analyze process flow. You may assume that the process operates full and at steady state (i.e., assumptions for Little's Law are appropriate). 11 Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 Step 7 Step 8 Step 9 Step 10 Step 11 Label each activity and Units 15 buffer in the top row of Inventory (Single Line) the table. Use as many Rate (Single Line) cells as necessary to Time (Single Line) show the whole process. Leave any extra cells blank if necessary. Report ALL answers with Z decimal places. 23 Provide 2 decimal Ansver Units places for all answers. 25 How much time is spent in value-adding activities, on average? 26 How much time is spent in buffers, on average? 17 18 19 20 21 22 24 NA What is the average amount of time it takes for a bottle to flow 27 through the entire process? What is the process flow efficiency ( % value add) for the 28 process? Show as a % with 2 decimal places (e.g. 2.56%) Based on how the process performs currently, what is the TOTAL annual production capacity of ALL LINES? (Assume no 29 time lost to setup/changeover). 30 How much inventory, on average, is in the process (ALL LINES)? How many bottles, on average, are lost each year due to 31 conformance quality failures (ALL LINES)? Type here to search o e w 10:41 AM 4/24/2021 10 ^ ENG 20 AutoSave On 2 HW1402_SPRING_2021 Version 1 (2) (1) (1) (1) - Saved - Search Rachid Sarhane RS File Home Insert Page Layout Formulas Data Review View Help Share Comments 11 Calibri 11 = = - AP > ab Wrap Text General 47 O FO Insert 3X Delete Format Paste .00 BIU A += = 3 Merge & Center $ % 40 .00 Conditional Format as Cell Formatting Table Styles Styles Sort & Find & Filter Select Analyze Data Clipboard Font Alignment Number Cells Editing Analysis 1112 X C. J K L P R S T U 25 26 B LACLIPOTIUT CICCICU VICTCK TUK TITS T-SUTUS TITUXITUMU TIIVUTT-SUCC. E mun Eng vua. H N 24 "Global sales of Invanz, for the treatment of certain infections, were $602 million in 2017, an increase of 7% compared with 2016, driven primarily by higher sales in the United States, reflecting higher pricing that was partially offset by lower demand, as well as higher demand in Brazil. Worldwide sales of Invanz were $561 million in 2016, a decline of 1% compared with 2015.... Sales performance in 27 2016 reflects higher pricing in the United States, largely offset by a decline in Venezuela. The patent that provided U.S. market exclusivity for invanz expired in November 2017 and the Company 28 anticipates a significant decline in U.S. Invanz sales in future periods. 29 32 33 34 35 30 After patent protection ends for Invanz, generic drug producers will likely introduce lower cost, generic versions of the product. The speed and size of generic entries will depend on numerous factors, 31 including the attractiveness of market entry by generic manufacturers, the investment required and the technological difficulty of manufacturing the product. While antibiotics such as Invanz are extremely capital-intensive and difficult to manufacture (due to processing complexity and the difficulty in maintaining acceptable conformance quality), generics are making inroads in Merck's other off-patent antibiotics. Patent protection for Primaxin ended in 2008 and a generic version entered the global market in 2010. 36 Merck lost patent protection for Invanz in the US in November 2017. On June 28, 2018, Aurobindo announced that the FDA had approved their generic versions have been approved for use in the US. 37 Aurobindo began selling generic Invanz in the US at the end of July 2018. 38 39 40 41 Invanz is an antibiotic of "last resort" meaning that it is typically only administered after other antibiotics have failed. The increasing incidence of infections that are resistant to more common antibiotics is expected to help offset inroads from generics. Clinical researchers estimate annual growth in demand for antibiotics such as Invanz in the low single digits annually for the foreseeable future due to increasing antibiotic resistance. 42 43 44 48 50 Demand for Invanz produced by Merck will be dependent in large part on Merck's ability to compete on cost as well as quality. Performance quality (i.e., the ability to successfully treat specific 45 infections) is an order winner. Conformance quality (i.e., meeting manufacturing specifications) is an order qualifier. Conformance quality issues are a serious concern; if poor quality product reaches 46 the market, patient safety could be at risk and the firm may need to conduct a product recall. Product recalls are typically damaging to the firm's stock price in the short term and potentially to the 47 firm's brand in the long term. Competing on cost will become increasingly important as new antibiotics enter the market and due to expected competition from firms producing generic versions of Invanz. Generic drug manufacturers may have higher quality risk when introducing new drugs, in part because they lack experience with the process. Merck has an advantage over Aurobindo in this 49 respect, at least initially, because they have lengthy production experience with the process. 51 52 Global sales of Invanz and Primaxin are provided below through the end of September 2018. A single dose of Invanz (1 bottle) retails, on average, at $1,315.56 per bottle; a single dose of Primaxin (1 53 bottle) is priced, on average, at $860.70 per bottle. You can assume that this pricing will remain constant over the period of the strategic plan and that generic competition is present worldwide as of 54 July 2018. You may assume that Aurobindo has a slight cost (price) advantage over Merck for Invanz, and that Aurobindo has adequate capacity to supply global demand for Invanz. A new strategic 55 plan is required for 2019-2023, including annual forecasts of sales of both products. 56 1. Scenario Details 2. Long Term Forecast | 3. Weekly Demand Forecast Sheet1 4. Process F... + Calculate + 70% H Type here to search O & . w AEC ENG 5:48 PM 4/13/2021 714 Content + AutoSave Off HD HW1&2_SPRING_2021 Version 1 (6) - Excel Search Rachid Sarhane RS File Home Insert Page Layout Formulas Data Review View Help Share Comments X Calibri 14 ' ' = > v a Wrap Text General AY o FO Insert 9X Delete Format Paste BIU a-A- ===== = .00 Merge & Center $ % Conditional Format as Cell Formatting Table Styles Styles Sort & Find & Filter Select Analyze Data Analysis Clipboard Font Alignment Number Cells Editing A31 X How many bottles, on average, are lost each year due to conformance quality failures (ALL LINES)? B c E F K L M N R R P s T U Y 5 FIRST AND LAST NAME 7 12 Step 12 Step 13 Step 14 Step 15 Step 16 13 14 16 Use the table below to show/calculate all steps of the process described (including activities and buffers). Provide the average inventory, rate, and time for each activity and buffer. 10 Use Little's Law and the data provided to analyze process flow. You may assume that the process operates full and at steady state (i.e., assumptions for Little's Law are appropriate). 11 Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 Step 7 Step 8 Step 9 Step 10 Step 11 Label each activity and Units 15 buffer in the top row of Inventory (Single Line) the table. Use as many Rate (Single Line) cells as necessary to Time (Single Line) show the whole process. Leave any extra cells blank if necessary. Report ALL answers with Z decimal places. 23 Provide 2 decimal Ansver Units places for all answers. 25 How much time is spent in value-adding activities, on average? 26 How much time is spent in buffers, on average? 17 18 19 20 21 22 24 NA What is the average amount of time it takes for a bottle to flow 27 through the entire process? What is the process flow efficiency ( % value add) for the 28 process? Show as a % with 2 decimal places (e.g. 2.56%) Based on how the process performs currently, what is the TOTAL annual production capacity of ALL LINES? (Assume no 29 time lost to setup/changeover). 30 How much inventory, on average, is in the process (ALL LINES)? How many bottles, on average, are lost each year due to 31 conformance quality failures (ALL LINES)? Type here to search o e w 10:41 AM 4/24/2021 10 ^ ENG 20